Dermata Therapeutics, Inc.
DRMA
$0.8721
-$0.0358-3.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.49% | 18.24% | 21.05% | 14.59% | -1.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.60% | 53.08% | 23.89% | -2.16% | -16.88% |
| Operating Income | -55.60% | -53.08% | -23.89% | 2.16% | 16.88% |
| Income Before Tax | -57.64% | -53.75% | -22.16% | 4.15% | 18.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.64% | -53.75% | -22.16% | 4.15% | 18.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.64% | -53.75% | -22.16% | 4.15% | 18.90% |
| EBIT | -55.60% | -53.08% | -23.89% | 2.16% | 16.88% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 75.64% | 76.27% | 78.93% | 81.88% | 73.35% |
| Normalized Basic EPS | 75.64% | 76.27% | 78.93% | 81.88% | 73.35% |
| EPS Diluted | 75.64% | 76.27% | 78.93% | 81.88% | 73.35% |
| Normalized Diluted EPS | 75.64% | 76.27% | 78.93% | 81.88% | 73.35% |
| Average Basic Shares Outstanding | 685.50% | 487.37% | 374.13% | 438.16% | 323.11% |
| Average Diluted Shares Outstanding | 685.50% | 487.37% | 374.13% | 438.16% | 323.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |